Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/198143
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease |
Autor: | Kovar, Heinrich; Amatruda, James; Brunet, Erika; Burdach, Stefan; Cidre-Aranaz, Florencia; Álava, Enrique de CSIC ORCID; Dirksen, Uta; van der Ent, Wietske; Grohar, Patrick; Grünewald, Thomas G. P.; Helman, Lee; Houghton, Peter; Iljin, Kristiina; Korsching, Eberhard; Ladanyi, Marc; Lawlor, Elizabeth; Lessnick, Stephen; Ludwig, Joseph; Meltzer, Paul; Meltzer, Markus; Mora, Jaume; Moriggl, Richard; Nakamura, Takuro; Papamarkou, Theodore; Sarikas, Branka Radic; Rédini, Francoise; Richter, Guenther H. S.; Rossig, Claudia; Schadler, Keri; Schäfer, Beat W.; Scotlandi, Katia; Sheffield, Nathan C.; Shelat, Anang; Snaar-Jagalska, Ewa; Sorensen, Poul; Stegmaier, Kimberly; Stewart, Elizabeth; Sweet-Cordero, Alejandro; Szuhai, Karoly; Tirado, Óscar M.; Tirode, Franck; Toretsky, Jeffrey; Tsafou, Kalliopi; Üren, Aykut; Zinovyev, Andrei; Delattre, Olivier | Palabras clave: | Ewing sarcoma Epigenetics Development Therapy Microenvironment |
Fecha de publicación: | 18-ene-2016 | Editor: | Impact Journals | Citación: | Oncotarget 7(8): 8613-8624 (2016) | Resumen: | Despite multimodal treatment, long term outcome for patients with Ewing sarcoma is still poor. The second >European interdisciplinary Ewing sarcoma research summit> assembled a large group of scientific experts in the field to discuss their latest unpublished findings on the way to the identification of novel therapeutic targets and strategies. Ewing sarcoma is characterized by a quiet genome with presence of an EWSR1-ETS gene rearrangement as the only and defining genetic aberration. RNAsequencing of recently described Ewing-like sarcomas with variant translocations identified them as biologically distinct diseases. Various presentations adressed mechanisms of EWS-ETS fusion protein activities with a focus on EWS-FLI1. Data were presented shedding light on the molecular underpinnings of genetic permissiveness to this disease uncovering interaction of EWS-FLI1 with recently discovered susceptibility loci. Epigenetic context as a consequence of the interaction between the oncoprotein, cell type, developmental stage, and tissue microenvironment emerged as dominant theme in the discussion of the molecular pathogenesis and inter- and intratumor heterogeneity of Ewing sarcoma, and the difficulty to generate animal models faithfully recapitulating the human disease. The problem of preclinical development of biologically targeted therapeutics was discussed and promising perspectives were offered from the study of novel in vitro models. Finally, it was concluded that in order to facilitate rapid pre-clinical and clinical development of novel therapies in Ewing sarcoma, the community needs a platform to maintain knowledge of unpublished results, systems and models used in drug testing and to continue the open dialogue initiated at the first two Ewing sarcoma summits. | Versión del editor: | http://dx.doi.org/10.18632/oncotarget.6937 | URI: | http://hdl.handle.net/10261/198143 | DOI: | 10.18632/oncotarget.6937 | Identificadores: | doi: 10.18632/oncotarget.6937 e-issn: 1949-2553 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
ewing_sarcoma_research_summit.pdf | 1,28 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
23
checked on 31-mar-2024
SCOPUSTM
Citations
37
checked on 15-abr-2024
WEB OF SCIENCETM
Citations
29
checked on 26-feb-2024
Page view(s)
148
checked on 20-abr-2024
Download(s)
105
checked on 20-abr-2024